Profile data is unavailable for this security.
About the company
Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in manufacturing of pharmaceutical preparations. The Company is involved in research and development innovations, production and commercialization of life-saving vaccines based on viral vectors for the delivery of antigens targeting infectious diseases. Bavarian Nordic A/S offers travel health products including cholera, rabies, tick-borne encephalitis and typhoid vaccines, as well as vaccines sold and distributed in selected markets on behalf of third parties. The Company deals with vaccines aimed at improving public health and preparedness. Bavarian Nordic A/S focuses on vaccine solutions that help address the threat of infectious diseases. The Company operates worldwide.
- Revenue in USD (TTM)1.10bn
- Net income in USD389.29m
- Incorporated1992
- Employees1.74k
- LocationBavarian Nordic A/SPhilip Heymans Alle 3HELLERUP 2900DenmarkDNK
- Websitehttps://www.bavarian-nordic.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sarepta Therapeutics Inc | 2.41bn | -271.51m | 1.92bn | 1.37k | -- | 1.45 | -- | 0.7958 | -3.19 | -3.19 | 22.09 | 12.60 | 0.6806 | 0.6977 | 5.81 | 1,759,268.00 | -7.66 | -12.82 | -9.92 | -15.47 | 76.25 | 85.53 | -11.25 | -37.16 | 1.79 | -- | 0.4395 | -- | 52.97 | 37.94 | 143.89 | -- | 18.57 | -- |
| Ocular Therapeutix Inc | 51.95m | -265.94m | 1.97bn | 325.00 | -- | 2.98 | -- | 37.84 | -1.44 | -1.44 | 0.2775 | 3.03 | 0.0821 | 1.99 | 1.65 | 159,849.20 | -42.01 | -38.63 | -45.31 | -43.31 | 87.35 | 90.18 | -511.90 | -229.54 | 15.32 | -- | 0.0983 | -- | -18.47 | 24.45 | -37.43 | -- | 70.20 | -- |
| Perrigo Company PLC | 4.28bn | -29.20m | 1.98bn | 8.38k | -- | 0.4453 | 6.54 | 0.4625 | -0.2128 | -0.3764 | 31.00 | 32.31 | 0.4023 | 2.34 | 5.75 | 511,015.60 | -0.2743 | -0.7059 | -0.3124 | -0.8082 | 35.46 | 34.96 | -0.682 | -1.76 | 1.44 | 2.41 | 0.4505 | -- | -6.06 | 2.48 | -3,552.27 | -- | -16.23 | 18.65 |
| Organon & Co | 6.30bn | 501.00m | 2.03bn | 10.00k | 4.06 | 2.24 | 2.41 | 0.3223 | 1.92 | 1.92 | 24.20 | 3.48 | 0.4791 | 1.97 | 3.98 | 630,100.00 | 3.81 | 11.52 | 4.81 | 14.94 | 55.04 | 62.30 | 7.95 | 20.24 | 1.20 | 2.50 | 0.9069 | 16.02 | 2.24 | -3.81 | -15.54 | -23.54 | 30.71 | -- |
| Phibro Animal Health Corp | 1.46bn | 92.09m | 2.10bn | 2.48k | 22.94 | 6.30 | 14.68 | 1.43 | 2.26 | 2.26 | 35.88 | 8.21 | 1.09 | 2.09 | 7.18 | 591,646.40 | 6.84 | 3.89 | 8.47 | 4.87 | 32.56 | 31.14 | 6.29 | 3.69 | 1.22 | 4.39 | 0.6875 | 52.02 | 27.37 | 10.12 | 1,897.68 | 7.54 | 2.38 | 0.00 |
| Avadel Pharmaceuticals PLC (ADR) | 248.52m | -278.00k | 2.12bn | 188.00 | -- | 21.41 | 624.80 | 8.54 | -0.0055 | -0.0055 | 2.53 | 1.01 | 1.39 | 1.11 | 6.25 | 1,321,899.00 | -0.1554 | -42.00 | -0.2203 | -50.53 | 91.09 | -- | -0.1119 | -194.15 | 2.37 | -0.5126 | 0.2618 | -- | 504.79 | 23.35 | 69.53 | -- | -- | -- |
| Harmony Biosciences Holdings Inc | 825.94m | 185.68m | 2.18bn | 246.00 | 11.95 | 2.62 | 10.43 | 2.65 | 3.18 | 3.18 | 14.13 | 14.50 | 0.7732 | 26.70 | 9.07 | -- | 17.38 | 15.64 | 21.20 | 19.13 | 77.70 | 79.78 | 22.48 | 20.61 | 3.72 | -- | 0.1679 | 0.00 | 22.80 | 160.18 | 12.91 | -- | -56.63 | -- |
| Ultragenyx Pharmaceutical Inc | 630.60m | -579.83m | 2.33bn | 1.29k | -- | 254.82 | -- | 3.70 | -5.94 | -5.94 | 6.46 | 0.095 | 0.4622 | 2.02 | 6.13 | 487,324.60 | -42.50 | -33.04 | -55.49 | -38.84 | 84.69 | 91.29 | -91.95 | -127.45 | 1.74 | -17.52 | 0.9809 | -- | 29.01 | 40.12 | 6.17 | -- | -4.24 | -- |
| Bavarian Nordic A/S - ADR | 1.10bn | 389.29m | 2.46bn | 1.74k | 6.33 | 1.15 | 4.91 | 2.25 | 1.62 | 1.62 | 4.55 | 8.92 | 0.4732 | 1.34 | 6.08 | 680,642.20 | 16.80 | 3.31 | 20.18 | 4.02 | 54.33 | 52.68 | 35.50 | 9.80 | 2.43 | -- | 0.0101 | -- | -19.06 | 53.88 | -33.03 | -- | -- | -- |
| Tarsus Pharmaceuticals Inc | 366.10m | -81.16m | 2.80bn | 323.00 | -- | 8.35 | -- | 7.64 | -2.01 | -2.01 | 8.99 | 7.89 | 0.8039 | 7.39 | 7.19 | 1,133,437.00 | -17.82 | -33.35 | -22.30 | -37.21 | 93.26 | -- | -22.17 | -125.04 | 4.25 | -- | 0.1774 | -- | 948.62 | -- | 14.97 | -- | 106.47 | -- |
| Apellis Pharmaceuticals Inc | 1.02bn | 44.99m | 2.86bn | 705.00 | 76.04 | 7.12 | 61.22 | 2.81 | 0.297 | 0.297 | 8.03 | 3.17 | 1.04 | 0.9298 | 3.25 | 1,441,698.00 | 4.59 | -61.31 | 6.04 | -76.53 | 88.85 | 86.49 | 4.43 | -157.26 | 3.10 | 2.51 | 0.5313 | -- | 97.02 | -- | 62.57 | -- | -24.96 | -- |
| Supernus Pharmaceuticals Inc | 681.54m | -19.12m | 2.93bn | 674.00 | -- | 2.79 | 44.26 | 4.31 | -0.3408 | -0.3408 | 12.09 | 18.38 | 0.4934 | 0.959 | 4.30 | 1,011,185.00 | -1.38 | 4.25 | -1.79 | 5.58 | 89.91 | 87.90 | -2.80 | 10.41 | 1.56 | -- | 0.00 | -- | 8.94 | 11.00 | 5,512.84 | -8.16 | -23.33 | -- |
| Catalyst Pharmaceuticals Inc | 578.20m | 217.56m | 2.98bn | 181.00 | 14.16 | 3.25 | 11.68 | 5.16 | 1.71 | 1.71 | 4.55 | 7.47 | 0.6341 | 3.45 | 7.02 | 3,194,453.00 | 23.86 | 24.62 | 27.38 | 28.82 | 85.68 | 85.77 | 37.63 | 31.73 | 6.40 | -- | 0.00 | 0.00 | 23.49 | 36.89 | 129.50 | 38.75 | 95.70 | -- |
Data as of Feb 11 2026. Currency figures normalised to Bavarian Nordic A/S's reporting currency: US Dollar USD
0.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RhumbLine Advisers LPas of 30 Sep 2025 | 4.31k | 0.00% |
| GAMMA Investing LLCas of 31 Dec 2025 | 19.00 | 0.00% |
| Curio Wealth LLCas of 30 Sep 2025 | 0.00 | 0.00% |
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
